Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05697328 · ClinicalTrials.gov registry record · NA
Barotrauma in Hyperbaric Oxygen Therapy
A NA study of Barotrauma, sponsored by John Muir Health.
- Recruiting
- Registry status
- NA
- Development phase
- 90
- Enrollment target
- 1
- Study location
NCT05697328: Recruiting NA study of Barotrauma, sponsored by John Muir Health.
NCT05697328 is a NA study of Barotrauma that is actively recruiting participants, run by John Muir Health. The registered enrollment target is 90 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05697328, a NA study of Barotrauma, is actively recruiting participants, sponsored by John Muir Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to study whether the use of pseudoephedrine can help prevent middle ear trauma during HBOT. Pseudoephedrine is an approved drug that is used for temporary relief of nasal or sinus pain and pressure.
Primary Outcome
Patients to describe pain on a numerical scale before, during and after hyperbaric oxygen therapy
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pseudoephedrine Pill
Study Locations (1)
California
- John Muir Health - Walnut Creek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2023-01-31 |
| Est. Completion | 2026-07 |
| Phase | NA |
What NCT05697328 shows while recruiting
NCT05697328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Barotrauma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05697328 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05697328 about?
NCT05697328 is a clinical study titled "Barotrauma in Hyperbaric Oxygen Therapy". The purpose of this research is to study whether the use of pseudoephedrine can help prevent middle ear trauma during HBOT. Pseudoephedrine is an approved drug that is used for temporary relief of nasal or sinus pain and pressure.
What is the current status of trial NCT05697328?
This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2023-01-31. Estimated completion is 2026-07.
What conditions does trial NCT05697328 study?
This clinical trial studies the following conditions: Barotrauma.
What interventions are being tested in trial NCT05697328?
The interventions under investigation include: Placebo (DRUG), Pseudoephedrine Pill (DRUG).
Who is sponsoring clinical trial NCT05697328?
This trial is sponsored by John Muir Health, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05697328 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05697328's enrollment target sits among peer trials
90 941st of 2000 higher than 1,029 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI